New quarterly revenue record, underscoring growth

10 November 2025

FOR PUBLIC RELEASE

Rua Bioscience sets new quarterly revenue record, underscoring growth

Rua Bioscience is pleased to announce a record revenue result for Q1 FY26 ending September
2025, marking a milestone in the company’s commercial growth. This achievement reflects Rua’s
ability to deliver strong sales outcomes across all key markets, including New Zealand, Australia,
and Germany.


The company’s best-ever sales performance highlights both growing demand for Rua’s
medicinal cannabis products and the effectiveness of its export-led commercial strategy. It also
demonstrates Rua’s ability to scale sales rapidly, provided appropriate funding is in place to
support supply and expansion.
Chief Executive Officer Paul Naske said, “This quarter’s results reaffirm that Rua can grow sales
effectively across markets. With continued access to funding, we are confident in our ability to
maintain this trajectory and expand further.”
$0.04m
$0.22m
$0.47m
$0.42m
$0.39m
$0.56m
FY24FY25FY25FY25FY25FY26
Q4Q1Q2Q3Q4Q1
(unaudited)
Customer revenue

Rua’s commercial progress aligns with its founding purpose: to create a high-value,
intergenerational company that delivers quality New Zealand-grown medicinal cannabis
products to patients at home and abroad. With channels now active in four international
markets and a growing product portfolio, Rua is positioned to grow further.

ENDS
The person who authorised this statement:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154